Rodman & Renshaw analyst Charles Anthony initiated coverage of Century Therapeutics with a Buy rating and $6 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPSC:
- Century Therapeutics Provides Investor Meeting Slide Update
- Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
- Century Therapeutics files to sell 7.87M shares of common stock for holders
- Century Therapeutics price target raised to $12 from $9 at Piper Sandler
Questions or Comments about the article? Write to editor@tipranks.com